Frontlight ResearchEarly access
Lung cancer trials in United States
900 trials · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 1/2Taking peopleA Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
- Where
- Chicago, Fairfax, Hackensack, Houston, Los Angeles, Louisville, New Haven, Phoenix, San Antonio
- Age
- 18 years and over
- People
- 180 worldwide
- Run by
- Alentis Therapeutics AG
See details and how to joinNCT07169734 · EU 2025-521441-24-00 - No phaseTaking peopleIdentification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers
- Where
- Stanford
- Age
- 18 years and over
- People
- 200
- Run by
- Stanford University
See details and how to joinNCT00568490 - No phaseTaking peopleEXoPERT EMERALD Clinical Study
- Where
- Albany, Baltimore, Honolulu, Lexington, Long Beach, Los Angeles, Louisville, The Bronx, Wappingers Falls
- Age
- 45 years and over
- People
- 1,400
- Run by
- EXoPERT
See details and how to joinNCT07186296 - No phaseTaking peopleKentucky - Quality Improvement Implementation Lung Cancer Screening (QUILS™) Implementation
- Where
- Ashland, Campbellsville, Edgewood, Georgetown, Glasgow, Hazard, Lexington, Louisville, Maysville, Morehead, Mount Vernon, Owensboro, Paducah, Somerset, Winchester
- Age
- 18 years to 100 years
- People
- 330
- Run by
- Timothy Mullett
See details and how to joinNCT07639255 - Phase 1Not yet taking people in United StatesInhaled Cromolyn Sodium in Patients With Locally Advanced Lung Cancer
- Where
- Denver
- Age
- 18 years and over
- People
- 10
- Run by
- Carcinex Inc
See details and how to joinNCT07675876 - Phase 2Not yet taking people in United StatesGCC 2545- Improving Post-Radiotherapy Respiratory Function Through Sparing Serial and Parallel Components in the Lung
- Where
- Baltimore
- Age
- 18 years and over
- People
- 70
- Run by
- University of Maryland, Baltimore
See details and how to joinNCT07679607 - Phase 1Taking peoplePapaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer
- Where
- Columbus, Duarte
- Age
- 18 years and over
- People
- 28
- Run by
- Ohio State University Comprehensive Cancer Center
See details and how to joinNCT05136846 - No phaseTaking peopleClonal Hematopoiesis Chemotherapy and Radiation Effects Study
- Where
- Boston
- Age
- 18 years and over
- People
- 5,000
- Run by
- Dana-Farber Cancer Institute
See details and how to joinNCT07675967 - No phaseTaking peopleIntegrated Cancer Repository for Cancer Research
- Where
- Aitkin, Alliance, Aurora, Bozeman, Brainerd, Canton, Council Bluffs, Daytona Beach, DeLand, Duluth, Fargo, Fayetteville, Fergus Falls, Fort Wayne, Glens Falls, Green Bay, Greenwood Village, Hastings, Holyoke, Kansas City, Liberty, Manchester, Minot, Norfolk, North Kansas City, North Platte, Omaha, Orange City, Overland Park, Palm Coast, Randallstown, Saint Joseph, Tallahassee, Utica, Waterloo, Westminster, Yorkville
- Age
- 19 years to 110 years
- People
- 999,999
- Run by
- University of Nebraska
See details and how to joinNCT02012699 - Early phase 1Taking peopleFeasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung
- Where
- Dallas
- Age
- 18 years and over
- People
- 30
- Run by
- University of Texas Southwestern Medical Center
See details and how to joinNCT06712745 - No phaseTaking peoplePredicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
- Where
- Forth Worth, Fort Smith, Frederick, Oklahoma City, Springfield, St Louis, Temple
- Age
- 18 years and over
- People
- 2,000
- Run by
- Elephas
See details and how to joinNCT07327489 - Phase 2Taking peopleAutologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
- Where
- Baltimore, Camden, Chapel Hill, Chicago, Cincinnati, Columbus, Detroit, Fargo, Gilbert, Knoxville, Louisville, Memphis, Miami, Minneapolis, Natrona Heights, New York, Omaha, Park Ridge, Portland, Richmond, Seattle, Sioux Falls, Tampa, Winston-Salem
- Age
- 18 years to 70 years
- People
- 170 worldwide
- Run by
- Iovance Biotherapeutics, Inc.
See details and how to joinNCT04614103 · EU 2024-510778-26-00 - Phase 1Taking peopleGilteritinib for the Treatment of ALK NSCLC
- Where
- Ann Arbor, Los Angeles, Washington D.C.
- Age
- 18 years and over
- People
- 30
- Run by
- University of Michigan Rogel Cancer Center
See details and how to joinNCT06225427 - No phaseTaking peoplePrediction Augmented Screening Initiative
- Where
- Ann Arbor, Bedford, Boston, Charleston
- Age
- 50 years to 80 years
- People
- 23,520
- Run by
- VA Office of Research and Development
See details and how to joinNCT06538636 - Phase 1Taking peopleSubcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)
- Where
- Ann Arbor, Chicago, Houston, Los Angeles, Seattle, Sioux Falls
- Age
- 18 years and over
- People
- 220 worldwide
- Run by
- Amgen
See details and how to joinNCT06598306 · EU 2024-511838-12-00 - No phaseTaking peopleGCC 2546- Motion Management
- Where
- Baltimore
- Age
- 18 years and over
- People
- 44
- Run by
- University of Maryland, Baltimore
See details and how to joinNCT07398209 - No phaseTaking peopleStudying Tumor Tissue Samples and Blood Samples to Learn More About DNA Changes in Patients With Lung Cancer
- Where
- Sacramento
- Age
- 18 years and over
- People
- 800
- Run by
- University of California, Davis
See details and how to joinNCT00899405 - Phase 1Taking peopleA Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
- Where
- Denver, Los Angeles, Nashville
- Age
- 18 years and over
- People
- 134
- Run by
- RasCal Therapeutics, Inc.
See details and how to joinNCT04678648 - Phase 1Taking peopleStudy to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- Where
- Austin, Chicago, Duarte, Durham, Fairfax, Fort Wayne, Grand Rapids, Houston, Huntersville, Indianapolis, Irvine, Irving, Los Angeles, Louisville, Minneapolis, Omaha, San Antonio, West Valley City
- Age
- 18 years and over
- People
- 694 worldwide
- Run by
- AbbVie
See details and how to joinNCT05005403 - No phaseTaking peopleExercise Training for the Improvement of Immune Activity and Treatment Outcomes During Immunotherapy for Non-small Cell Lung Cancer, BOOST Trial
- Where
- Seattle
- Age
- 18 years and over
- People
- 100
- Run by
- Fred Hutchinson Cancer Center
See details and how to joinNCT06983899 - Phase 3Taking peopleAglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)
- Where
- New York
- Age
- 18 years and over
- People
- 500
- Run by
- Candel Therapeutics, Inc.
See details and how to joinNCT07660094 - No phaseTaking peopleEvaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
- Where
- Rochester
- Age
- 18 years and over
- People
- 500
- Run by
- Mayo Clinic
See details and how to joinNCT06075524 - No phaseTaking peopleBeating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer
- Where
- Columbus
- Age
- 18 years and over
- People
- 3,584
- Run by
- Ohio State University Comprehensive Cancer Center
See details and how to joinNCT03199651 - Phase 1/2Taking peopleDose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer
- Where
- Greenwich, Guilford, Hamden, New Haven, Trumbull, Waterford
- Age
- 18 years and over
- People
- 36
- Run by
- Yale University
See details and how to joinNCT04210492 - Phase 2Taking peopleSX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer
- Where
- Seattle
- Age
- 18 years and over
- People
- 30
- Run by
- University of Washington
See details and how to joinNCT05570825